PATENT CLAIM ANALYSIS

Application Number: 16109143
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "489000"]

Abstract:
A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.

Claim (Index 7):
The oral suspension according to  claim 5  wherein said 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride is micronized.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 96.0
- Lexical Diversity: 1.14286
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14353141', '14994497', '13990515', '13989541', '13268387']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7306287989492626
- 35 USC 102 Novelty (BERT): 0.5827946122744658
- Combined Prediction Score: 0.7158453802817829
- Mean Citation Score: 335.881978
- Max Citation Score: 480.33377
- Similarity Product: 402.20015821995855

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test